

Glaucoma guideline committee meeting 5

Date: 16/01/2017

NICE National Institute for
Health and Care Excellence

Location: Boardroom, National Guideline Centre, 180 Great Portland Street,
London W1W 5QZ

Minutes: Confirmed

Committee members present:	
John Sparrow (JS, Chair)	(Present for notes 1–6)
Augusto Azuara Blanco (AAB)	(Present for notes 1–6)
Anomika Bedi (AB)	(Present for notes 1–6)
Jane Bell (JB)	(Present for notes 1–6)
Kamal Bishai (KB)	(Present for notes 1–6)
Helen Doe (HD)	(Present for notes 1–6)
Clare Faulkner (CF)	(Present for notes 1–6)
Cecilia Fenerty (CFen)	(Present for notes 1–6)
Paul Foster (PF)	(Present for notes 1–6)
Robert Harper (RH)	(Present for notes 1–6) Withdrew from discussions for items 4 and 5.
David Parkins (DP)	(Present for notes 1–6)
Rebecca Turner (RT)	(Present for notes 1–6)

In attendance:		
Ben Doak (BD)	Guideline Commissioning Manager, NICE	(Present for notes 1–6)
Anne-Louise Clayton (ALC)	Editor, NICE	(Present for notes 1–4b)
Meredith Faust (MF)	Document Editor/Process Assistant, NGC	(Present for notes 1–6)
Jessica Glen (JG)	Senior Research Fellow, NGC	(Present for notes 1–6)
Jennifer Hill (JH)	Operations	(Present for notes 1–6)

	Director/Guideline Lead, NGC	
Ben Pordes (BP)	Acting Senior Project Manager, NGC	(Present for notes 1–6)
Emma Pottinger (EP)	Research Fellow, NGC	(Present for notes 1–6)
Lauren Ramjee (LR)	Health Economist, NGC	(Present for notes 1–6)
Hannah Trippier (HT)	Senior Research Fellow, NGC	(Present for notes 1–6)

Apologies:

Jane Lynn (JL)	Business Analyst – Resource Impact Assessment Team, NICE
Jill Cobb (JC)	Information Specialist, NGC
Elisabetta Fenu (EF)	Health Economics Lead, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the fifth meeting on Glaucoma: diagnosis and management. The committee members and attendees introduced themselves.

No members of the public asked to observe the meeting.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included evidence reviews for IOP and anterior chamber angles as well as health economics model.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was IOPs, occludable anterior chamber angles, a treatment summary of clinical evidence, and the health economic model.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

There were no new declarations.

The Chair and a senior member of the Developer’s team noted that the following members would not participate in a part of the meeting:

- Robert Harper was unable to participate in the sections on treatment due to a previous declaration regarding pharmacological treatments. As

<p>agreed, he remained in the meeting room to listen but did not participate in the discussion.</p>
<p>3. Minutes of last meeting</p>
<p>The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.</p> <p>The Chair confirmed that all matters arising had been completed or were in hand.</p>
<p>4. Questions and discussion</p>
<p>a. The committee discussed the evidence for the question: ‘What is the accuracy of tests for measuring IOP and monitoring changes in IOP, including repeat measures?’ and were given the opportunity to ask questions.</p> <p>b. The committee discussed the evidence for the question: ‘What is the accuracy of tests for identifying closed or occludable anterior chamber angle?’ and were given the opportunity to ask questions.</p> <p>c. The committee discussed the summary of the clinical evidence for the treatment of glaucoma and were given the opportunity to ask questions.</p>
<p>5. Health economic model</p>
<p>The Chair introduced Lauren Ramjee, Health Economist at the NGC, who presented the Health Economic Model.</p> <p>LR took questions from the group.</p> <p>The committee thanked LR for her presentation and contribution to the development of the guideline.</p>
<p>6. Any other business:</p>
<p>BP organised the committee into individual subgroups.</p>

Date of next meeting: GC6 – 28/02/2017 GC7 – 01/03/2017

Location of next meeting: Boardroom, NGC, 180 Great Portland Street, London W1W 5QZ